When BOTOX Reduces Migraines but Doesn’t Eliminate Them: What Families Should Expect

Imagine a parent named Elena.

For years, migraine attacks have shaped her family calendar. A Saturday trip to the park can turn into an afternoon in a dark bedroom. A school event gets missed. Dinner plans are canceled. Her partner takes over bedtime because light, noise, nausea, and head pain have become too much.

After being evaluated for chronic migraine, Elena begins preventive BOTOX treatment.

A few months later, something important happens.

She still gets migraines.

At first, that feels disappointing. Elena had hoped that treatment would make every migraine disappear. But when she looks at her headache diary, she notices something else: there are fewer migraine days than before. She has attended more of her children’s activities. She has missed fewer workdays. Some attacks are easier to manage, and she has more predictable stretches of time when she feels like herself.

Treatment has not produced perfection.

It has produced progress.

That distinction is important for families considering BOTOX for chronic migraine.

BOTOX Is a Preventive Treatment, Not a Promise of Zero Migraines

BOTOX, or onabotulinumtoxinA, is FDA-approved for the prevention of headaches in adults with chronic migraine. The current prescribing information describes its use in adults experiencing at least 15 headache days per month, with headaches lasting four hours a day or longer. Its safety and effectiveness have not been established for preventing episodic migraine in patients with 14 or fewer headache days per month (AbbVie, 2026).

That does not mean every person with frequent headaches automatically qualifies for BOTOX.

Migraine diagnosis, headache frequency, previous treatment, medications, medical history, neurological symptoms, pregnancy considerations, other health conditions, and individual risks all need to be reviewed by an appropriately licensed healthcare professional.

Families can learn more about the clinical distinction between episodic and chronic migraine in Dr. Jimenez’s BOTOX Chronic Migraine Treatment: 2026 Clinical Guide.

Most importantly, BOTOX is preventive care. It is not an emergency injection intended to immediately stop a migraine that has already started.

The goal is to reduce the migraine burden over time.

Success Does Not Always Mean Becoming Headache-Free

People understandably want a treatment to make their problem disappear.

Migraine prevention usually requires a more realistic definition of success.

The American Headache Society has emphasized that preventive-treatment goals should focus on decreasing migraine frequency, severity, and overall burden rather than promising complete elimination of attacks. A substantial reduction in migraine frequency can represent meaningful treatment success even if some attacks continue (American Headache Society, 2020).

The updated 2026 American Academy of Neurology and American Headache Society guideline takes a similarly patient-centered approach. It recommends considering not only the number of migraine days but also disability, quality of life, side effects, treatment preferences, medical conditions, and the patient’s goals when deciding whether preventive treatment is helping (Potrebic et al., 2026).

For someone like Elena, success could therefore mean:

• fewer headache or migraine days each month;
• fewer attacks that become severely disabling;
• more days when she can work consistently;
• fewer canceled family plans;
• better participation in exercise and daily activities;
• less disruption of sleep and household routines;
• reduced migraine-related disability; and
• more confidence when planning life several days in advance.

Those changes may sound less dramatic than saying, “My migraines are gone.”

For a family living around chronic migraine, however, they can be enormously meaningful.

What the Research Tells Us About Migraine Reduction

Large clinical studies help put these expectations into perspective.

The PREEMPT clinical trial program studied onabotulinumtoxinA as preventive treatment for chronic migraine. In pooled research, people treated with onabotulinumtoxinA experienced significant improvements in headache impact and migraine-specific quality of life compared with placebo (Lipton et al., 2011).

Longer-term evaluations also found sustained improvements in quality-of-life measures during repeated treatment cycles (Lipton et al., 2016).

These findings matter because headache-day counts tell only part of the story.

Migraine affects whether someone can drive a child to practice, concentrate during a meeting, tolerate the sounds of a busy household, prepare dinner, exercise, sleep normally, or simply make plans without wondering whether pain will interfere.

Clinical improvement can therefore be measured both in migraine numbers and in life regained.

One Family May Notice Improvement Before Another

Migraine treatment is highly individual.

One patient might experience a major reduction in headache frequency. Another may still have frequent headaches but notice shorter or less disruptive attacks. Someone else may need several treatment cycles before the clinician can fairly determine whether BOTOX is providing sufficient benefit.

The FDA-approved treatment protocol also reflects the preventive nature of therapy. For chronic migraine, the prescribing information recommends 155 Units divided among 31 injection sites across specific head and neck muscle areas, with retreatment generally performed every 12 weeks (AbbVie, 2026).

The 2026 AAN/AHS guideline recommends allowing an adequate treatment period before deciding the treatment has failed. Evaluate the response systematically rather than judging the entire treatment by what happens in the first few days or weeks (Potrebic et al., 2026).

This is one reason a headache diary can be so valuable.

A Headache Diary Can Show Progress That Memory Misses

When migraine has been part of life for years, patients may have difficulty remembering exactly how many bad days occurred three months ago.

A simple diary can track:

• headache days;
• migraine days;
• severity;
• attack duration;
• nausea or sensory sensitivity;
• medications used;
• missed work;
• interrupted sleep;
• canceled activities; and
• days when normal family activities were possible.

Suppose Elena had 20 headache days during an average month before treatment.

Several months later, she still has 11.

Eleven headache days are certainly not ideal. She still needs medical management, and her treatment plan may need continued reassessment.

But she has also gained nine additional days during which headache is no longer dominating her schedule.

Those nine days might include a birthday party, a full week of work, a school concert, two family dinners, and an uninterrupted night’s sleep.

A number on a headache calendar can translate into very real changes at home.

Fewer Migraine Days Can Change Family Life

Migraine rarely affects only the person experiencing the attack.

Children may learn that certain days require quieter play. Partners may pick up household responsibilities. Family members may change plans at the last minute. Work schedules can become harder to predict, and poor sleep following an attack can affect the following day as well.

That is why quality-of-life improvement deserves attention alongside pain reduction.

If prevention decreases migraine burden, a parent may become more available for ordinary moments that previously felt difficult.

They may be able to attend a soccer game without worrying about bright sunlight. They may finish the workday more consistently. They may be present for dinner rather than retreating to a quiet room. They may sleep better because fewer evenings are dominated by pain, nausea, or post-migraine fatigue.

None of these improvements mean the underlying migraine disorder has magically vanished.

They mean treatment may be giving the patient more usable life between attacks.

What If Migraines Continue?

Continuing to have migraines after BOTOX does not automatically mean treatment has failed.

The healthcare team can review several questions:

Has Headache Frequency Changed?

Compare the number of monthly headache and migraine days before and after treatment.

Has Disability Changed?

A patient may still experience attacks but miss fewer workdays or family activities.

Has Attack Severity Changed?

Some people notice that attacks become more manageable even when they still occur.

Has Acute Medication Use Changed?

Medication use should be reviewed carefully because frequent use of certain acute headache medicines can complicate migraine management.

Has Enough Time Passed?

Clinicians evaluate preventive migraine treatment over time. Clinicians may need more than one treatment cycle to understand the patient’s response.

Is Something Else Contributing?

Sleep problems, medication changes, hormonal factors, neck pain, stress, other headache disorders, and underlying medical conditions may influence the clinical picture.

These questions help shift the conversation from “Did BOTOX cure my migraines?” to the more useful question: “Is my migraine burden meaningfully better?”

Migraine Treatment May Require More Than One Strategy

Chronic migraine is complex.

BOTOX may be one component of treatment, not the entire plan.

Depending on the patient’s circumstances, migraine management may also include acute migraine medication, another preventive strategy, sleep and lifestyle interventions, rehabilitation for associated musculoskeletal problems, and evaluation of other health conditions.

The 2026 migraine-prevention guideline emphasizes shared decision-making because no single treatment approach fits everyone (Potrebic et al., 2026).

Patients interested in the broader relationship between migraine, cervical complaints, medical evaluation, lifestyle factors, and rehabilitation can also review Dr. Jimenez’s Integrated Migraine Treatment El Paso: Complete Clinical Guide or explore the clinic’s Headaches & Treatments educational library. The clinic appropriately notes that chiropractic treatment may address coexisting mechanical neck complaints but should not be presented as a cure for migraine.

What Makes Dr. Jimenez’s Integrated Clinic Different?

At Injury Medical Chiropractic and Functional Medicine Clinic in El Paso, patients can receive migraine evaluation within a multidisciplinary healthcare environment.

Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, serves in both chiropractic and advanced-practice nursing roles. His clinical background includes musculoskeletal and soft-tissue injury evaluation, physical medicine, rehabilitation, functional health, and medical assessment within his licensed scope. Dr. Maria Guadalupe Cardenas, MD, a board-certified internal medicine physician, serves as Medical Director and Collaborative Physician, providing medical oversight and helping coordinate more complex medical concerns. The clinic’s current public information specifically lists migraine BOTOX among its available services.

This integrated structure can be especially helpful when a migraine patient also has neck pain, sleep disruption, a previous soft-tissue injury, medication concerns, metabolic conditions, or other health issues that deserve evaluation.

Multidisciplinary care is not meant to force every patient into every available therapy. It is to determine which treatments are clinically appropriate, which are unnecessary, and when referral or coordination with a neurologist, primary-care physician, or another specialist is needed.

Patients remain active decision-makers throughout that process.

BOTOX Safety Still Matters

Preventive treatment requires realistic expectations about risks and benefits.

In chronic migraine trials, reported adverse reactions occurring more frequently with BOTOX than placebo included neck pain, muscular weakness or stiffness, eyelid drooping, injection-site pain, headache, and other musculoskeletal complaints. The BOTOX prescribing information also includes a boxed warning about the potential distant spread of botulinum toxin effects, which, in uncommon circumstances, can produce serious symptoms (AbbVie, 2026).

Patients should tell their treating clinician about their medical conditions, previous botulinum toxin treatment, medications, muscle or nerve disorders, swallowing or breathing problems, pregnancy considerations, and other relevant health information.

Individual medical evaluation matters.

Sometimes the Most Important Change Is the Plan That Doesn’t Get Canceled

Several months after beginning treatment, Elena still keeps migraine medication nearby.

She still knows which room in the house has the best blackout curtains.

And occasionally, she still has to tell her family, “I have a migraine today.”

But those days happen less often.

One Saturday, she realizes the family has made it through an entire month without canceling a planned weekend outing because of her headaches.

That moment does not appear on a laboratory report.

It will not necessarily show up as a dramatic medical statistic.

But it is exactly the kind of improvement preventive migraine treatment is intended to make possible.

For families living with chronic migraine, treatment success does not always mean eliminating every attack.

Sometimes it means getting enough days back to participate in life again.

Patients who believe their headache pattern may meet criteria for chronic migraine can discuss their symptoms, headache history, previous treatments, potential risks, and treatment goals with a qualified healthcare professional. Patients can request appointments with Dr. Jimenez’s El Paso clinic through the clinic’s online appointment scheduler, or call 915-850-0900 for information.

---

References

AbbVie Inc. (2026). BOTOX® (onabotulinumtoxinA) prescribing information. BOTOX Prescribing Information

American Headache Society. (2020). Choosing the right preventive treatment. American Headache Society preventive-treatment guidance

Lipton, R. B., Rosen, N. L., Ailani, J., DeGryse, R. E., Gillard, P. J., & Varon, S. F. (2016). OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program. Cephalalgia, 36(9), 899–908. PubMed record

Lipton, R. B., Varon, S. F., Grosberg, B., McAllister, P. J., Freitag, F., Aurora, S. K., Dodick, D. W., Silberstein, S. D., Diener, H. C., DeGryse, R. E., Nolan, M. E., & Turkel, C. C. (2011). OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology, 77(15), 1465–1472. PubMed record

Potrebic, S., Tanveer, S., Becker, W. J., Burch, R., Cooke, L. J., Fenton, T., Fletcher, J. J., Gordon Perue, G. L., Hershey, A. D., Jackson, J. L., Kessel, S., Loder, E. W., Minen, M. T., Oskoui, M., Ramanan, V. K., Murren, M., Schwedt, T. J., Silberstein, S. D., Smith, D. B., … Pringsheim, T. (2026). Pharmacologic treatment for migraine prevention in adults practice guideline recommendations: Report of the AAN Guidelines Subcommittee and the American Headache Society. Headache, 66(9), 2173–2184. 2026 AAN/AHS migraine prevention guideline